NZ193011A
(en)
|
1979-03-19 |
1983-03-15 |
Ici Australia Ltd |
Diarylamine derivatives intermediates herbicidal compositions
|
ES2054725T3
(es)
|
1987-04-21 |
1994-08-16 |
Basf Ag |
Heteroaromatos anulares de cinco miembros de p-fenoxi-fenoximetilo.
|
JP3121061B2
(ja)
|
1991-10-04 |
2000-12-25 |
塩野義製薬株式会社 |
アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体
|
DE4137940A1
(de)
|
1991-11-18 |
1993-05-19 |
Basf Ag |
3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
|
US5258551A
(en)
|
1991-12-18 |
1993-11-02 |
Shionogi & Co., Ltd. |
Process for producing α-ketoamide derivative
|
WO1994017059A1
(en)
|
1993-01-29 |
1994-08-04 |
Nippon Soda Co., Ltd. |
Heterocyclic derivative
|
WO1994024095A1
(en)
|
1993-04-16 |
1994-10-27 |
Abbott Laboratories |
Immunosuppressive agents
|
IL112721A0
(en)
|
1994-03-10 |
1995-05-26 |
Zeneca Ltd |
Azole derivatives
|
JPH10503768A
(ja)
|
1994-08-02 |
1998-04-07 |
メルク シヤープ エンド ドーム リミテツド |
アゼチジン、ピロリジンおよびピペリジン誘導体
|
GB9501865D0
(en)
|
1995-01-31 |
1995-03-22 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5633272A
(en)
|
1995-02-13 |
1997-05-27 |
Talley; John J. |
Substituted isoxazoles for the treatment of inflammation
|
DE19536811A1
(de)
|
1995-10-02 |
1997-04-03 |
Basf Ag |
Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
|
ES2183140T3
(es)
|
1996-02-13 |
2003-03-16 |
Searle & Co |
Combinaciones, que tienen efectos inmunosupresores, que contienen un inhibidor de ciclooxigenasa-2 y un inhibidor de leucotrieno a4 hidrolasa.
|
EP1140079B1
(en)
|
1998-12-23 |
2009-06-03 |
Glaxo Group Limited |
Assays for ligands for nuclear receptors
|
JP2003502337A
(ja)
|
1999-06-11 |
2003-01-21 |
アラーガン・セイルズ・インコーポレイテッド |
核ホルモン受容体調節活性を有するオルガノシリル化合物
|
CA2429426A1
(en)
|
2000-11-17 |
2002-05-23 |
Takeda Chemical Industries, Ltd. |
Isoxazole derivatives
|
US20040105883A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
|
US20040105884A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Pharmaceutical dosage form comprising a sulfite compound
|
US20040105885A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Gelatin capsule exhibiting reduced cross-linking
|
US20040131670A1
(en)
|
2001-04-17 |
2004-07-08 |
Ping Gao |
Pellicle-resistant gelatin capsule
|
US7223791B2
(en)
|
2001-06-26 |
2007-05-29 |
Takeda Pharmaceutical Company Limited |
Function regulator for retinoid relative receptor
|
DE60131967D1
(de)
|
2001-08-13 |
2008-01-31 |
Phenex Pharmaceuticals Ag |
Nr1h4-kern-rezeptor-bindende verbindungen
|
EP1423113A4
(en)
|
2001-08-13 |
2007-04-18 |
Phenex Pharmaceuticals Ag |
NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
|
WO2003016280A1
(en)
|
2001-08-13 |
2003-02-27 |
Lion Bioscience Ag |
Nr1h4 nuclear receptor binding compounds
|
US20050107475A1
(en)
|
2002-03-21 |
2005-05-19 |
Jones Stacey A. |
Methods of using farnesoid x receptor (frx) agonists
|
US7595311B2
(en)
|
2002-05-24 |
2009-09-29 |
Exelixis, Inc. |
Azepinoindole derivatives as pharmaceutical agents
|
TW200812986A
(en)
|
2002-08-09 |
2008-03-16 |
Nps Pharma Inc |
New compounds
|
RU2352568C9
(ru)
|
2002-08-09 |
2009-06-27 |
Астразенека Аб |
[1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
|
WO2004014902A2
(en)
|
2002-08-09 |
2004-02-19 |
Astrazeneca Ab |
Compounds having an activity at metabotropic glutamate receptors
|
EP1407774A1
(en)
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
WO2004046162A2
(en)
|
2002-11-14 |
2004-06-03 |
The Scripps Research Institute |
Non-steroidal fxr agonists
|
US20050143449A1
(en)
|
2002-11-15 |
2005-06-30 |
The Salk Institute For Biological Studies |
Non-steroidal farnesoid X receptor modulators and methods for the use thereof
|
WO2004048349A1
(en)
|
2002-11-22 |
2004-06-10 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
WO2004087076A2
(en)
|
2003-03-31 |
2004-10-14 |
The Rockefeller University |
Methods for inhibiting adipogenesis and for treating type 2 diabetes
|
WO2005077345A1
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Compounds for the treatment of gastro-esophageal reflux disease
|
WO2005077373A2
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Treatment of gastro-esophageal reflux disease (gerd)
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
EP1745027A4
(en)
|
2004-05-14 |
2009-06-03 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS
|
MY144903A
(en)
|
2004-06-17 |
2011-11-30 |
Novartis Ag |
Pyrrolopyridine derivatives and their use as crth2 antagonists
|
US9051342B2
(en)
|
2004-10-13 |
2015-06-09 |
Ptc Therapeutics, Inc. |
Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases
|
JP2008137894A
(ja)
|
2005-03-22 |
2008-06-19 |
Nippon Kayaku Co Ltd |
新規なアセチレン誘導体
|
JP5147109B2
(ja)
|
2005-06-07 |
2013-02-20 |
塩野義製薬株式会社 |
I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
|
CA2633243C
(en)
|
2005-12-15 |
2014-05-27 |
Exelixis, Inc. |
Azepinoindole derivatives as pharmaceutical agents
|
JP5081161B2
(ja)
|
2005-12-19 |
2012-11-21 |
スミスクライン ビーチャム コーポレーション |
ファルネソイドx受容体アゴニスト
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
CN101374834B
(zh)
|
2006-02-03 |
2011-12-14 |
伊莱利利公司 |
用于调节fxr的化合物和方法
|
CA2642220A1
(en)
|
2006-02-14 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
|
US20070276050A1
(en)
|
2006-02-27 |
2007-11-29 |
Gilead Sciences, Inc. |
Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases
|
EP2001851A2
(en)
|
2006-03-28 |
2008-12-17 |
Novartis AG |
Amide derivatives and their application for the treament of g protein related diseases
|
US20090286806A1
(en)
|
2006-04-17 |
2009-11-19 |
Hassan Pajouhesh |
Isoxazole derivatives as calcium channel blockers
|
JP5225984B2
(ja)
|
2006-05-24 |
2013-07-03 |
イーライ リリー アンド カンパニー |
Fxrを調節する化合物及び方法
|
EP2029600B1
(de)
|
2006-05-24 |
2012-03-14 |
Boehringer Ingelheim International GmbH |
Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
|
WO2007140183A1
(en)
|
2006-05-24 |
2007-12-06 |
Eli Lilly And Company |
Fxr agonists
|
CA2656320C
(en)
|
2006-06-27 |
2015-04-28 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
|
WO2008005538A2
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
PE20080401A1
(es)
|
2006-07-07 |
2008-06-23 |
Boehringer Ingelheim Int |
DERIVADOS DE HETEROARIL-FENIL SUSTITUIDOS COMO INHIBIDORES DE B-Raf-QUINASAS
|
US20080032990A1
(en)
|
2006-07-07 |
2008-02-07 |
Khalifah Raja G |
Inhibitors of advanced glycation end products
|
EP1894928A1
(en)
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
EP1894924A1
(en)
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
US8193225B2
(en)
|
2006-10-13 |
2012-06-05 |
The Board Of Regents Of The University Of Texas System |
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
US8501933B2
(en)
|
2006-11-09 |
2013-08-06 |
Roche Palo Alto Llc |
Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
|
JP5399262B2
(ja)
|
2006-12-08 |
2014-01-29 |
エグゼリクシス パテント カンパニー エルエルシー |
Lxrおよびfxrのモジュレーター
|
GB0625842D0
(en)
|
2006-12-22 |
2007-02-07 |
Argenta Discovery Ltd |
Indolizine derivatives
|
US20090105251A1
(en)
|
2007-01-25 |
2009-04-23 |
Benjamin Jones |
Renin inhibitors
|
BRPI0721218A2
(pt)
|
2007-02-09 |
2013-01-01 |
Dow Agrosciences Llc |
processo para a oxidação de determinadas sulfiliminas substituìdas para sulfoximinas inseticidas
|
US7511149B2
(en)
|
2007-02-09 |
2009-03-31 |
Dow Agrosciences Llc |
Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
|
KR101437710B1
(ko)
|
2007-02-26 |
2014-09-03 |
다우 아그로사이언시즈 엘엘씨 |
특정 치환된 술필이민의 제조 방법
|
JP2010529996A
(ja)
|
2007-06-13 |
2010-09-02 |
グラクソスミスクライン エルエルシー |
ファルネソイドx受容体アゴニスト
|
JP2008308448A
(ja)
|
2007-06-15 |
2008-12-25 |
Sankyo Agro Kk |
(3−硫黄原子置換フェニル)へテロアリール誘導体
|
WO2008155054A1
(en)
|
2007-06-20 |
2008-12-24 |
F. Hoffmann-La Roche Ag |
Farnesoid-x-receptor mutants, and crystallisation thereof
|
WO2009003998A2
(en)
|
2007-07-02 |
2009-01-08 |
Boehringer Ingelheim International Gmbh |
Antiproliferative compounds based on 5-membered heterocycles
|
WO2009005998A1
(en)
|
2007-07-02 |
2009-01-08 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
US20090197880A1
(en)
|
2007-07-13 |
2009-08-06 |
Genelabs Technologies, Inc. |
Anti-viral compounds, compositions, and methods of use
|
BRPI0814300A2
(pt)
|
2007-07-13 |
2015-02-03 |
Glaxosmithkline Llc |
Composto, composição farmacêutica, e, método para tratar uma infecção viral
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
EA201070189A1
(ru)
|
2007-08-01 |
2010-08-30 |
Х. Лундбекк А/С |
Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
|
US8188080B2
(en)
|
2007-10-17 |
2012-05-29 |
Sanford-Burnham Medical Research Institute |
VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
|
US20090143451A1
(en)
|
2007-11-14 |
2009-06-04 |
Andrews William H |
Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
|
AU2008339572B2
(en)
|
2007-12-21 |
2012-05-10 |
Astrazeneca Ab |
Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
JP2011520884A
(ja)
|
2008-05-13 |
2011-07-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Cb2受容体を変調するスルホン化合物
|
CA2723424A1
(en)
|
2008-05-19 |
2009-11-26 |
Burnham Institute For Medical Research |
Intestinal alkaline phosphatase modulators and uses thereof
|
WO2009143018A2
(en)
|
2008-05-19 |
2009-11-26 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
WO2009152083A1
(en)
|
2008-06-10 |
2009-12-17 |
Plexxikon, Inc. |
5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
CA2727078A1
(en)
|
2008-06-23 |
2009-12-30 |
Basf Se |
Sulfoximinamide compounds for combating animal pests
|
US20100029655A1
(en)
|
2008-07-11 |
2010-02-04 |
Martin Robert Leivers |
Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
|
US8044214B2
(en)
|
2008-08-25 |
2011-10-25 |
Angus Chemical Company |
Process for preparing isoxazole compounds
|
WO2010033906A2
(en)
|
2008-09-19 |
2010-03-25 |
President And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
JP5450632B2
(ja)
|
2008-09-25 |
2014-03-26 |
エフ.ホフマン−ラ ロシュ アーゲー |
3−アミノ−インダゾール又は3−アミノ−4,5,6,7−テトラヒドロインダゾール誘導体
|
CA2735886A1
(en)
|
2008-09-25 |
2010-04-01 |
F. Hoffmann-La Roche Ag |
Indazole or 4,5,6,7-tetrahydro-indazole derivatives
|
CA2736880A1
(en)
|
2008-09-26 |
2010-04-01 |
Wyeth Llc |
1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
|
NZ592603A
(en)
|
2008-10-21 |
2013-02-22 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof
|
US8637505B2
(en)
|
2009-02-04 |
2014-01-28 |
Boehringer Ingelheim International Gmbh |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
KR20100092909A
(ko)
|
2009-02-13 |
2010-08-23 |
주식회사 엘지생명과학 |
잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
|
FR2943059A1
(fr)
|
2009-03-16 |
2010-09-17 |
Sanofi Aventis |
Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
|
EP2451808B1
(en)
|
2009-07-06 |
2014-03-26 |
Basf Se |
Pyridazine compounds for controlling invertebrate pests
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
EP2456308A2
(en)
|
2009-07-24 |
2012-05-30 |
Basf Se |
Pyridine derivatives for controlling invertrebate pests
|
US9212177B2
(en)
|
2009-08-05 |
2015-12-15 |
Versitech Limited |
Antiviral compounds and methods of making and using thereof
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
WO2011026241A1
(en)
|
2009-09-04 |
2011-03-10 |
Zalicus Pharmaceuticals Ltd. |
Substituted heterocyclic derivatives for the treatment of pain and epilepsy
|
US9095596B2
(en)
|
2009-10-15 |
2015-08-04 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
CA2791738C
(en)
|
2010-03-01 |
2020-06-09 |
Gtx, Inc. |
Aryl imidazolyl compounds for the treatment of cancer
|
EP2580213A4
(en)
|
2010-06-09 |
2013-12-25 |
Afraxis Holdings Inc |
8- (HETEROARYLMETHYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
|
WO2012058531A2
(en)
|
2010-10-29 |
2012-05-03 |
North Carolina State University |
Modulation of response regulators by imidazole derivatives
|
TWI408128B
(zh)
|
2010-12-03 |
2013-09-11 |
Nat Univ Tsing Hua |
間-三聯苯衍生物及其在有機發光二極體之應用
|
CU24152B1
(es)
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
EP2655368A1
(en)
|
2010-12-20 |
2013-10-30 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
CN103391937A
(zh)
|
2010-12-20 |
2013-11-13 |
Irm责任有限公司 |
用于调控法尼醇x受体的组合物和方法
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
TWI701253B
(zh)
|
2011-11-11 |
2020-08-11 |
美商基利阿波羅有限責任公司 |
Acc抑制劑及彼等之用途
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
EP3336097B1
(en)
|
2012-06-19 |
2020-08-19 |
Intercept Pharmaceuticals, Inc. |
Preparation of the non-crystalline form of obeticholic acid
|
TWI621618B
(zh)
|
2013-03-13 |
2018-04-21 |
比利時商健生藥品公司 |
經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
|
WO2014181287A1
(en)
|
2013-05-09 |
2014-11-13 |
Piramal Enterprises Limited |
Heterocyclyl compounds and uses thereof
|
BR112015028152A2
(pt)
|
2013-05-10 |
2017-07-25 |
Nimbus Apollo Inc |
inibidores de acc e usos dos mesmos
|
EP3360882B1
(en)
|
2013-05-14 |
2020-12-09 |
Intercept Pharmaceuticals, Inc. |
11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
|
CN105593237B
(zh)
|
2013-08-01 |
2019-06-04 |
美国卫生和人力服务部 |
法尼醇x受体的抑制剂和在医学中的用途
|
JP6366721B2
(ja)
|
2013-09-11 |
2018-08-01 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
B型肝炎ウイルス感染症を処置するための方法及び医薬組成物
|
US20150082981A1
(en)
|
2013-09-20 |
2015-03-26 |
E I Du Pont De Nemours And Company |
Capture of trifluoromethane using ionic liquids
|
CN104513213A
(zh)
|
2013-09-28 |
2015-04-15 |
山东亨利医药科技有限责任公司 |
Fxr激动剂
|
US20150119345A1
(en)
|
2013-10-29 |
2015-04-30 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of gastrointestinal infections
|
TN2016000143A1
(en)
|
2013-11-05 |
2017-10-06 |
Novartis Ag |
Compositions and methods for modulating farnesoid x receptors.
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
WO2015138986A1
(en)
|
2014-03-13 |
2015-09-17 |
Salk Institute For Biological Studies |
Fxr agonists and methods for making and using
|
KR20160133529A
(ko)
|
2014-03-13 |
2016-11-22 |
더 솔크 인스티튜트 포 바이올로지칼 스터디즈 |
펙사라민 유도체 및 이의 제조와 사용 방법
|
US10077268B2
(en)
|
2014-03-13 |
2018-09-18 |
Salk Institute For Biological Studies |
FXR agonists and methods for making and using
|
MX2016013447A
(es)
|
2014-04-14 |
2017-01-18 |
Gruenenthal Gmbh |
Heterociclilsulfonas heteroarilo sustituidas.
|
WO2015162538A1
(en)
|
2014-04-21 |
2015-10-29 |
Lupin Limited |
Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
|
WO2015162244A1
(en)
|
2014-04-25 |
2015-10-29 |
Basf Se |
N-acylamidine compounds
|
WO2015165960A1
(en)
|
2014-04-30 |
2015-11-05 |
Basf Se |
N-acylamidine compounds
|
ES2768718T3
(es)
|
2014-05-29 |
2020-06-23 |
Bar Pharmaceuticals S R L |
Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1
|
CN104045635A
(zh)
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
US9855249B2
(en)
|
2014-10-02 |
2018-01-02 |
Flatley Discovery Lab, Llc |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
EP3214151B1
(en)
|
2014-10-27 |
2020-10-14 |
LG Chem, Ltd. |
Organic electroluminescence device
|
US10266560B2
(en)
|
2014-11-06 |
2019-04-23 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
SG10202010386PA
(en)
|
2014-11-21 |
2020-11-27 |
Akarna Therapeutics Ltd |
Fused bicyclic compounds for the treatment of disease
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
WO2016086134A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
WO2016086115A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
CA2968404A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
CN107106555A
(zh)
|
2014-12-18 |
2017-08-29 |
诺华股份有限公司 |
氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用
|
CA2972919A1
(en)
|
2015-01-09 |
2016-07-14 |
Gilead Apollo, Llc |
Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
|
CA2973873A1
(en)
|
2015-01-20 |
2016-07-28 |
Merial, Inc. |
Anthelmintic compounds, compositions and method of using thereof
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
US10100285B2
(en)
|
2015-04-03 |
2018-10-16 |
Propagenix Inc. |
Ex vivo proliferation of epithelial cells
|
CN106146483A
(zh)
|
2015-04-23 |
2016-11-23 |
上海迪诺医药科技有限公司 |
杂环类法尼酯衍生物x受体调节剂
|
GB201507340D0
(en)
|
2015-04-29 |
2015-06-10 |
Univ St Andrews |
Light emitting devices and compounds
|
CN107920523A
(zh)
|
2015-07-13 |
2018-04-17 |
范德比尔特大学 |
Orco激动剂的热挥发
|
JP6869231B2
(ja)
|
2015-09-11 |
2021-05-12 |
プロパジェニクス インコーポレイテッド |
ex vivoでの上皮細胞の増殖
|
EP3383860B1
(en)
|
2015-12-04 |
2021-01-20 |
Bristol-Myers Squibb Company |
Apelin receptor agonists and methods of use
|
WO2017097870A1
(de)
|
2015-12-11 |
2017-06-15 |
Bayer Cropscience Aktiengesellschaft |
Substituierte malonsäureamide als insektizide
|
CN106946867B
(zh)
|
2016-01-06 |
2019-11-12 |
广州市恒诺康医药科技有限公司 |
Fxr受体调节剂及其制备方法和用途
|
EP3190103A1
(en)
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
WO2017117687A1
(en)
|
2016-01-10 |
2017-07-13 |
British Columbia Cancer Agency Branch |
18/19f-labelled compounds which target the prostate specific membrane antigen
|
WO2017122209A2
(en)
|
2016-01-12 |
2017-07-20 |
Yeda Research And Development Co. Ltd. |
NF-kappaB INHIBITORS
|
WO2017128896A1
(zh)
|
2016-01-26 |
2017-08-03 |
江苏豪森药业集团有限公司 |
Fxr激动剂及其制备方法和应用
|
CN107021957A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
CN107021958A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
WO2017133521A1
(zh)
|
2016-02-01 |
2017-08-10 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
TW201741307A
(zh)
|
2016-02-22 |
2017-12-01 |
艾洛斯生物製藥公司 |
Fxr調節劑及其使用方法
|
CN107224583A
(zh)
|
2016-03-24 |
2017-10-03 |
中美华世通生物医药科技(武汉)有限公司 |
药物组合物及其用途
|
WO2017189652A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
US10080743B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
WO2017201150A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
US10138228B2
(en)
|
2016-05-18 |
2018-11-27 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use therof
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
SG11201810602YA
(en)
|
2016-06-03 |
2018-12-28 |
Chemocentryx Inc |
Method of treating liver fibrosis
|
EP3468953B1
(en)
|
2016-06-13 |
2024-05-22 |
GlaxoSmithKline Intellectual Property Development Limited |
Substituted pyridines as inhibitors of dnmt1
|
SG11201810600WA
(en)
|
2016-06-13 |
2018-12-28 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
AR108711A1
(es)
|
2016-06-13 |
2018-09-19 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4)
|
CA2968836A1
(en)
|
2016-06-13 |
2017-12-13 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
MA46052A
(fr)
|
2016-08-23 |
2021-03-17 |
Ardelyx Inc |
Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
|
WO2018039384A1
(en)
|
2016-08-23 |
2018-03-01 |
Ardelyx, Inc. |
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
|
CN108430998B
(zh)
|
2016-09-28 |
2021-07-09 |
四川科伦博泰生物医药股份有限公司 |
氮杂双环衍生物及其制备方法和用途
|
EP3519408A1
(en)
|
2016-09-29 |
2019-08-07 |
Bayer CropScience Aktiengesellschaft |
1 -[2-(1 -chlorocyclopropyl)-2-hydroxy-3-(3-phenyl-1,2-oxazol-5-yl)propyl]-1h-imidazole-5-carbonitrile derivatives and related compounds as fungicides for crop protection
|
RU2019113066A
(ru)
|
2016-10-04 |
2020-11-09 |
Энанта Фармасьютикалс, Инк. |
Аналоги изоксазола как агонисты fxr и способы их применения
|
KR20190109387A
(ko)
*
|
2016-10-18 |
2019-09-25 |
마드리갈 파마슈티칼스, 인크. |
Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
|
CN107973790A
(zh)
|
2016-10-22 |
2018-05-01 |
合帕吉恩治疗公司 |
杂环fxr调节剂
|
CN110191724A
(zh)
|
2016-11-10 |
2019-08-30 |
盖尔梅德研究与发展有限公司 |
纤维化的治疗
|
WO2018089212A1
(en)
*
|
2016-11-11 |
2018-05-17 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
CN106588804B
(zh)
|
2016-12-09 |
2018-11-09 |
都创(上海)医药科技有限公司 |
一种作为类法尼醇x受体(fxr)的化合物的制备方法
|
CN106632294A
(zh)
|
2016-12-15 |
2017-05-10 |
宁波百纳西药业有限公司 |
一种螺环化合物及其药物用途
|
CN106748922B
(zh)
|
2017-01-12 |
2019-02-01 |
中国药科大学 |
一类新型砜酸衍生物、其制备方法及其作为药物的用途
|
JP6906626B2
(ja)
*
|
2017-03-28 |
2021-07-21 |
ギリアード サイエンシーズ, インコーポレイテッド |
肝疾患を処置するための治療的組み合わせ
|
TW201902478A
(zh)
|
2017-04-12 |
2019-01-16 |
美商基利科學股份有限公司 |
治療肝臟疾病之方法
|
WO2018190643A1
(en)
|
2017-04-12 |
2018-10-18 |
Il Dong Pharmaceutical Co., Ltd. |
An isoxazole derivatives as nuclear receptor agonists and used thereof
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ, インコーポレイテッド |
Fxrアゴニストの固体形態
|
CA3132044A1
(en)
|
2019-03-11 |
2020-09-17 |
Brian Kirby |
Formulations of a compound and uses thereof
|